Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024

ALT 11.04.2024

SERA-AI Powered Highlights
Date of Upcoming Event:2024-11-12
Name of Upcoming Event:Altimmune Investor Relations Conference Call
Full Press ReleaseSEC FilingsOur ALT Tweets

About Gravity Analytica

Recent News

  • 01.07.2025 - Annabel Samimy
  • 12.19.2024 - Altimmune Added to Nasdaq Biotechnology Index
  • 12.06.2024 - 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders

Recent Filings

  • 01.03.2025 - 4 Statement of changes in beneficial ownership of securities
  • 12.11.2024 - 8-K Current report
PDF Version

GAITHERSBURG, Md.,Nov. 04, 2024(GLOBE NEWSWIRE) --Altimmune, Inc.(Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2024 financial results onTuesday, November 12, 2024and will provide a business update.

Altimmune management will host a conference call at8:30 am E.T.onNovember 12to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website athttps://ir.altimmune.com/investors.

Participants who would like to join the call may registerhereto receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor Relations website for up to three months.

About AltimmuneAltimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visitwww.altimmune.com.

Follow @Altimmune, Inc. onLinkedInFollow @AltimmuneInc onTwitter

Company Contact:Vipin GargPresident and Chief Executive OfficerPhone: 240-654-1450ir@altimmune.com

Investor Contacts:Lee RothBurns McClellanPhone: 646-382-3403lroth@burnsmc.com

Julia WeilmanBurns McClellanPhone: 646-732-4443jweilman@burnsmc.com

Media Contact:Danielle CanteyInizio Evoke, BiotechPhone: 619-826-4657Danielle.cantey@inizioevoke.com

This press release was published by a CLEAR® Verified individual.

Primary Logo

Source: Altimmune, Inc

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com